Current and future diagnostic approaches: From serologies to imaging

被引：14

作者：

Bruining D.H. ^{[1
]}

Loftus Jr. E.V. ^{[1
]}

机构：

[1] Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905

来源：

Current Gastroenterology Reports | 2007年 / 9卷 / 6期

关键词：

Capsule Endoscopy; Chronic Ulcerative Colitis; Magnetic Resonance Enterography; Magnetic Resonance Enteroclysis; Magnetic Resonance Colonography;

D O I：

10.1007/s11894-007-0065-5

中图分类号：

学科分类号：

摘要：

Advances in serologic markers and imaging modalities continue to revolutionize diagnostic approaches to inflammatory bowel disease (IBD). Autoimmune and antimicrobial antibodies demonstrate diagnostic value in those patients with a moderate pretest probability of disease. Emerging data also support the use of antimicrobial antibody levels as a predictive tool for small bowel complications and the need for future surgery. In addition to being a prognostic marker in patients with acute severe colitis, serum C-reactive protein has been shown to correlate with clinical, endoscopic, and radiologic measures of disease activity. Capsule endoscopy and double-balloon endoscopy allow for visualization of the entire small bowel, and double-balloon endoscopy also has the capability to treat lessions. CT enterography is beginning to replace small bowel follow-through because of its high sensitivity and specificity for disease of the small intestine. Both CT and magnetic resonance enterography detect luminal and extraluminal abnormalities, with MRI serving as a safe imaging option in cases of pregnancy and renal insufficiency. These newer modalities add to the armamentarium clinicians can use for evaluation of IBD. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：489 / 496

页数：7

共 106 条

[1]

Bossuyt X., Serologic markers in inflammatory bowel disease, Clin Chem, 52, pp. 171-181, (2006)

[2]

Gupta N., Cohen S.A., Bostrom A.G., Et al., Risk factors for initial surgery in pediatric patients with Crohn's disease, Gastroenterology, 130, pp. 1069-1077, (2006)

[3]

Koutroubakis I.E., Petinaki E., Mouzas I.A., Et al., Anti-Saccharomyces cerevisiae mannan antibodies and anti-neutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease, Am J Gastroenterol, 96, pp. 449-454, (2001)

[4]

Quinton J.F., Sendid B., Reumaux D., Et al., Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: Prevalence and diagnostic role, Gut, 42, pp. 788-791, (1998)

[5]

Arnott I.D., Landers C.J., Nimmo E.J., Et al., Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype, Am J Gastroenterol, 99, pp. 2376-2384, (2004)

[6]

Iltanen S., Tervo L., Halttunen T., Et al., Elevated serum anti-12 and anti-OmpW antibody levels in children with IBD, Inflamm Bowel Dis, 12, pp. 389-394, (2006)

[7]

Kaila B., Orr K., Bernstein C.N., The anti-Saccharomyces cerevisiae antibody assay in a province-wide practice: Accurate in identifying cases of Crohn's disease and predicting inflammatory disease, Can J Gastroenterol, 19, pp. 717-721, (2005)

[8]

Damoiseaux J.G., Bouten B., Linders A.M., Et al., Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies for inflammatory bowel disease: High prevalence in patients with celiac disease, J Clin Immunol, 22, pp. 281-288, (2002)

[9]

Holstein A., Burmeister J., Plaschke A., Et al., Autoantibody profiles in microscopic colitis, J Gastroenterol Hepatol, 21, pp. 1016-1020, (2006)

[10]

Dubinsky M.C., Lin Y.C., Dutridge D., Et al., Serum immune responses predict rapid disease progression among children with Crohn's disease: Immune responses predict disease progression, Am J Gastroenterol, 101, pp. 360-367, (2006)

← 1 2 3 4 5 6 7 8 9 10 →